Airway clearance management in people with bronchiectasis: data from the European Bronchiectasis Registry (EMBARC)
-
Published:2024-04-12
Issue:6
Volume:63
Page:2301689
-
ISSN:0903-1936
-
Container-title:European Respiratory Journal
-
language:en
-
Short-container-title:Eur Respir J
Author:
Spinou AriettaORCID, Hererro-Cortina Beatriz, Aliberti StefanoORCID, Goeminne Pieter C., Polverino Eva, Dimakou Katerina, Haworth Charles S., Loebinger Michael R., De Soyza AnthonyORCID, Vendrell Montserrat, Burgel Pierre RegisORCID, McDonnell MelissaORCID, Sutharsan Sivagurunathan, Škrgat Sabina, Maiz-Carro Luiz, Sibila Oriol, Stolz Daiana, Kauppi Paula, Bossios ApostolosORCID, Hill Adam T., Clifton Ian, Crichton Megan L., Walker Paul, Menendez Rosario, Borekci Sermin, Obradovic Dusanka, Nowinski Adam, Amorim Adelina, Torres AntoniORCID, Lorent NatalieORCID, Welte TobiasORCID, Blasi Francesco, Jankovic Makek MatejaORCID, Shteinberg MichalORCID, Boersma Wim, Elborn J. Stuart, Chalmers James D., Ringshausen Felix C.ORCID
Abstract
BackgroundInternational guidelines recommend airway clearance management as one of the important pillars of bronchiectasis treatment. However, the extent to which airway clearance is used for people with bronchiectasis in Europe is unclear. The aim of the study was to identify the use of airway clearance management in patients with bronchiectasis across different countries and factors influencing airway clearance use.MethodsThis was a prospective observational study using data from the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) Registry between January 2015 and April 2022. Prespecified options for airway clearance management were recorded, including airway clearance techniques, devices and use of mucoactive drugs.Results16 723 people with bronchiectasis from 28 countries were included in the study. The mean age was 67 years (interquartile range 57–74 years, range 18–100 years) and 61% were female. 72% of the participants reported daily sputum expectoration and 52% (95% CI 51–53%) of all participants reported using regular airway clearance management. Active cycle of breathing technique was used by 28% of the participants and airway clearance devices by 16% of participants. The frequency of airway clearance management and techniques used varied significantly between different countries. Participants who used airway clearance management had greater disease severity and worse symptoms, including a higher daily sputum volume, compared to those who did not use it regularly. Mucoactive drugs were also more likely to be used in participants with more severe disease. Access to specialist respiratory physiotherapy was low throughout Europe, but particularly low in Eastern Europe.ConclusionsOnly a half of people with bronchiectasis in Europe use airway clearance management. Use of and access to devices, mucoactive drugs and specialist chest physiotherapy appears to be limited in many European countries.
Funder
European Respiratory Society
Publisher
European Respiratory Society (ERS)
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|